Form 8-K - Current report:
SEC Accession No. 0001193125-24-257295
Filing Date
2024-11-13
Accepted
2024-11-13 16:40:01
Documents
15
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d860903d8k.htm   iXBRL 8-K 25477
2 EX-99.1 d860903dex991.htm EX-99.1 61545
6 GRAPHIC g860903g1114012030312.jpg GRAPHIC 6803
  Complete submission text file 0001193125-24-257295.txt   229805

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA scph-20241113.xsd EX-101.SCH 2881
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE scph-20241113_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scph-20241113_pre.xml EX-101.PRE 11282
17 EXTRACTED XBRL INSTANCE DOCUMENT d860903d8k_htm.xml XML 3633
Mailing Address 25 BURLINGTON MALL ROAD, SUITE 203 BURLINGTON MA 01803
Business Address 25 BURLINGTON MALL ROAD, SUITE 203 BURLINGTON MA 01803 617-517-0730
scPharmaceuticals Inc. (Filer) CIK: 0001604950 (see all company filings)

EIN.: 465184075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38293 | Film No.: 241455079
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)